Immutep Ltd (AU:IMM) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Immutep Ltd is making strides in the battle against non-small cell lung cancer (NSCLC) by advancing its clinical candidate, eftilagimod alpha (efti), into a Phase III trial. This promising drug is being tested in combination with KEYTRUDA and chemotherapy, aiming to enhance patient outcomes in one of the largest oncology markets. With strong financial backing and a strategic collaboration with MSD, Immutep is poised to potentially establish a new standard of care for NSCLC patients.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
